Cargando…
HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in herniorrhaphy: results from the phase 3 EPOCH 2 study
PURPOSE: Currently available local anesthetics have not demonstrated sufficient analgesia beyond 12–24 h postoperatively. The purpose of the study was to assess the safety and efficacy of HTX-011 (bupivacaine and meloxicam in Biochronomer(®) polymer technology), a long-acting investigational anesthe...
Autores principales: | Viscusi, E., Minkowitz, H., Winkle, P., Ramamoorthy, S., Hu, J., Singla, N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Paris
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938470/ https://www.ncbi.nlm.nih.gov/pubmed/31429023 http://dx.doi.org/10.1007/s10029-019-02023-6 |
Ejemplares similares
-
Opioid-Free Recovery After Hernia Repair with HTX-011 as the Foundation of a Non-Opioid, Multimodal Analgesia Regimen in a Real-World Setting: A Randomized, Open-Label Study
por: Minkowitz, Harold, et al.
Publicado: (2021) -
Pharmacokinetics and Safety of INL-001 (Bupivacaine HCl) Implants Compared with Bupivacaine HCl Infiltration After Open Unilateral Inguinal Hernioplasty
por: Leiman, David, et al.
Publicado: (2020) -
HTX-011: Another game changer multimodal analgesic or an ephemeral, experimental drug!
por: Nair, Abhijit, et al.
Publicado: (2020) -
Efficacy of New Long-Acting Bupivacaine HTX-011 in Providing Pain Relief for Patients Undergoing Elective Surgery – A Meta-analysis of Prospective Randomized Controlled Trials
por: Goudra, Basavana, et al.
Publicado: (2020) -
Response to the letter to the editor by Hafer and Johnson concerning ‘Mechanism of action of HTX-011: a novel, extended-release, dual-acting local anesthetic formulation for postoperative pain’
por: Ottoboni, Thomas, et al.
Publicado: (2020)